Home › Therapeutic areas › Oncology › Acute Myeloid Leukemia
Acute Myeloid Leukemia (16 companies)
Companies with an active program in Acute Myeloid Leukemia.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $61.4M | 9 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $256M | 10 |
| APVO | Aptevo Therapeutics | Oncology | 1 | Phase 1 | $1.6M | 8 |
| BMEA | Biomea Fusion | MetabolicOncology | 1 | Phase 2 | $35.5M | 4 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $602M | 10 |
| GERN | Geron | Oncology | 1 | Approved | $644M | 3 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $8.9M | 4 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $688M | 13 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.0M | 5 |
| MBRX | Moleculin Biotech | Oncology | 1 | Phase 2 | $7.3M | 9 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.04B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | 1 | Phase 2 | $1.69B | 6 |
| SLS | SELLAS Life Sciences Group | Oncology | 2 | Phase 3 | $3.90B | 9 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $822M | 7 |
| TLX | Telix Pharmaceuticals | Oncology | 1 | Approved | $3.01B | 25 |
| HURA | TuHURA Biosciences | Oncology | 1 | Phase 3 | $92.1M | 4 |
No companies match.